These advanced therapies can be tailored to specific disease contexts, such as mitigating T cell dysfunction in chronic lymphocytic leukemia (CLL) [44] or enhancing CAR T activity via co-expression of C-X-C motif chemokine ligand 13 (CXCL13) to potentiate PD-1 blockade responses [45]. The gene discussed is CXCL13; the disease is B-cell chronic lymphocytic leukemia.